ORIC Oric Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORIC

Price (delayed)

$7.67

Market cap

$516.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.96

Enterprise value

$493.39M

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist ...

Highlights
The EPS has increased by 13% year-on-year
The quick ratio has declined by 24% year-on-year and by 15% since the previous quarter
ORIC's net income is down by 13% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://oricpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ORIC
Market
Shares outstanding
67.38M
Market cap
$516.77M
Enterprise value
$493.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$100.7M
EBITDA
-$99.67M
Free cash flow
-$86.54M
Per share
EPS
-$1.96
Free cash flow per share
-$1.68
Book value per share
$4.11
Revenue per share
$0
TBVPS
$4.9
Balance sheet
Total assets
$252.01M
Total liabilities
$27.92M
Debt
$0
Equity
$224.09M
Working capital
$192.14M
Liquidity
Debt to equity
0
Current ratio
10.39
Quick ratio
10.18
Net debt/EBITDA
0.23
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-38.6%
Return on equity
-42.7%
Return on invested capital
-52.7%
Return on capital employed
-43.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORIC stock price

How has the Oric Pharmaceuticals stock price performed over time
Intraday
-5.07%
1 week
-19.35%
1 month
-43.02%
1 year
53.09%
YTD
-16.63%
QTD
-44.22%

Financial performance

How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$110.78M
Net income
-$100.7M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 21% year-on-year and by 9% since the previous quarter
ORIC's net income is down by 13% year-on-year and by 8% since the previous quarter

Growth

What is Oric Pharmaceuticals's growth rate over time

Valuation

What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 13% year-on-year
The stock's P/B is 25% more than its last 4 quarters average of 1.5
Oric Pharmaceuticals's equity has decreased by 9% QoQ

Efficiency

How efficient is Oric Pharmaceuticals business performance
The return on equity has declined by 11% year-on-year and by 8% since the previous quarter
The ROA has declined by 10% year-on-year and by 8% since the previous quarter
Oric Pharmaceuticals's return on invested capital has decreased by 4.8% YoY

Dividends

What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORIC.

Financial health

How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 24% year-on-year and by 15% since the previous quarter
The company's current ratio fell by 24% YoY and by 15% QoQ
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.